1.1 Ribociclib, with an aromatase inhibitor, is recommended within its marketing authorisation, as an option for treating hormone receptor-positive, human epidermal growth factor receptor 2‑negative, locally advanced or metastatic breast cancer as initial endocrine-based therapy in adults. Ribociclib is recommended only if the company provides it with the discount agreed in the patient access scheme.
Why the committee made this recommendation
Clinical trial evidence shows that ribociclib plus letrozole improves progression-free survival compared with letrozole alone. Although we do not know yet if this improvement leads to a survival benefit with ribociclib. But with the patient access scheme discount, ribociclib is a cost-effective use of NHS resources and it can be recommended.